ACE inhibitor use delays development of renal involvement in patients with systemic lupus erythematosus (SLE). In a study of 378 SLE patients, 80 (21%) were ACE inhibitor users and 298 (79%) were not.

Angiotensin-converting enzyme (ACE) inhibitors are the mainstay of therapy for patients with systemic sclerosis in scleroderma renal crisis, however mortality remains high even in the post-ACE ...

Please provide your email address to receive an email when new articles are posted on . There was a significant independent link between angiotensin-converting enzyme inhibitor use and all-cause ...

ACE inhibitors may reduce all-cause mortality in IPF patients, suggesting potential repurposing for this progressive disease. The study used electronic health records from 3579 IPF patients, matched ...